Company intelligence / Profile preview

Genomictree

Yuseong, Daejeon, South Koreagenomictree.com ↗

Ownership: Private
Employees: ~81
Development stage: Preclinical

Overview

Genomictree has developed and commercialized non-invasive molecular diagnostic tests based on proprietary DNA methylation biomarker platforms. Their EarlyTect® product line is available commercially for early detection of colorectal, lung, and bladder cancers. Additional programs are in clinical development or validation stages. The company also offers multiplexed PCR assays for infectious disease detection including COVID‑19.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Diagnostic testPCR-based assayBiomarker-based molecular diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

EarlyTect

Pre-clinical

Indications: Colorectal cancer

Partnerships

Not specified in search results; likely collaborations with hospitals/universities for clinical studies

Beyond the preview

Go deeper on Genomictree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomictree.

Explore the full profile